Brief: Zhaoke Ophthalmology Says NMPA Acceptance Of New Drug Application For NVK002
Jan 2 (Reuters) - Zhaoke Ophthalmology Ltd 6622.HK :
* NMPA ACCEPTANCE OF ABBREVIATED NEW DRUG- APPLICATION FOR
NVK002
FOR TREATMENT OF- MYOPIA PROGRESSION IN CHILDREN
Further company coverage: 6622.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Zhaoke Ophthalmology
See all newsBrief: Zhaoke Ophthalmology Says Its Facility In Guangzhou Obtains GMP Certification From Australia's TGA
China's Zhaoke Ophthalmology H1 revenue rises
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved By Macau Pharmaceutical Administration Bureau
Brief: Zhaoke Ophthalmology Enters Into Definitive Agreement For Acquisition Of Global Rights To NVK002
Brief: Zhaoke Ophthalmology Says Yuvezzitm Approved For Use At Boao Super Hospital